268 related articles for article (PubMed ID: 32065408)
1. The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up.
Skalleberg J; Småstuen MC; Oldenburg J; Osnes T; Fosså SD; Bunne M
Laryngoscope; 2020 Sep; 130(9):E515-E521. PubMed ID: 32065408
[TBL] [Abstract][Full Text] [Related]
2. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
Haugnes HS; Stenklev NC; Brydøy M; Dahl O; Wilsgaard T; Laukli E; Fosså SD
Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420
[TBL] [Abstract][Full Text] [Related]
3. Speech perception 30 years after cisplatin-based chemotherapy in adults: limited clinical relevance of long-term ototoxicity?
Skalleberg J; Myhrum M; Småstuen MC; Osnes TA; Fosså SD; Bunne M
Acta Oncol; 2021 Apr; 60(4):426-433. PubMed ID: 33617403
[TBL] [Abstract][Full Text] [Related]
4. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy.
Weissenstein A; Deuster D; Knief A; Zehnhoff-Dinnesen AA; Schmidt CM
Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):131-6. PubMed ID: 22104469
[TBL] [Abstract][Full Text] [Related]
5. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
Skalleberg J; Solheim O; Fosså SD; Småstuen MC; Osnes T; Gundersen POM; Bunne M
Gynecol Oncol; 2017 Apr; 145(1):148-153. PubMed ID: 28202195
[TBL] [Abstract][Full Text] [Related]
6. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
7. Extended high-frequency ototoxicity induced by the first administration of cisplatin.
Sakamoto M; Kaga K; Kamio T
Otolaryngol Head Neck Surg; 2000 Jun; 122(6):828-33. PubMed ID: 10828794
[TBL] [Abstract][Full Text] [Related]
8. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments.
Ardeshirrouhanifard S; Fossa SD; Huddart R; Monahan PO; Fung C; Song Y; Dolan ME; Feldman DR; Hamilton RJ; Vaughn D; Martin NE; Kollmannsberger C; Dinh P; Einhorn L; Frisina RD; Travis LB
Ear Hear; 2022; 43(3):794-807. PubMed ID: 35067571
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy.
Sanchez VA; Dinh PC; Rooker J; Monahan PO; Althouse SK; Fung C; Sesso HD; Einhorn LH; Dolan ME; Frisina RD; Travis LB
J Cancer Surviv; 2023 Feb; 17(1):27-39. PubMed ID: 36637632
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Hearing Loss Among a Representative Sample of Canadian Children and Adolescents, 3 to 19 Years of Age.
Feder KP; Michaud D; McNamee J; Fitzpatrick E; Ramage-Morin P; Beauregard Y
Ear Hear; 2017; 38(1):7-20. PubMed ID: 27556530
[TBL] [Abstract][Full Text] [Related]
11. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
[TBL] [Abstract][Full Text] [Related]
12. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
Bokemeyer C; Berger CC; Hartmann JT; Kollmannsberger C; Schmoll HJ; Kuczyk MA; Kanz L
Br J Cancer; 1998 Apr; 77(8):1355-62. PubMed ID: 9579846
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
Frisina RD; Wheeler HE; Fossa SD; Kerns SL; Fung C; Sesso HD; Monahan PO; Feldman DR; Hamilton R; Vaughn DJ; Beard CJ; Budnick A; Johnson EM; Ardeshir-Rouhani-Fard S; Einhorn LH; Lipshultz SE; Dolan ME; Travis LB
J Clin Oncol; 2016 Aug; 34(23):2712-20. PubMed ID: 27354478
[TBL] [Abstract][Full Text] [Related]
14. Are There Cochlear Dead Regions Involved in Hearing Loss after Cisplatin Ototoxicity?
Schultz C; Pecora Liberman PH; Schmidt Goffi-Gomez MV
Audiol Neurootol; 2019; 24(5):253-257. PubMed ID: 31661686
[TBL] [Abstract][Full Text] [Related]
15. The importance of high-tone audiometry in monitoring for ototoxicity.
Tange RA; Dreschler WA; van der Hulst RJ
Arch Otorhinolaryngol; 1985; 242(1):77-81. PubMed ID: 3899068
[TBL] [Abstract][Full Text] [Related]
16. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a cisplatin dose-ototoxicity model.
Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
[TBL] [Abstract][Full Text] [Related]
18. Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors.
Hjelle LV; Gundersen POM; Hellesnes R; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Bremnes RM; Haugnes HS
Acta Oncol; 2018 Oct; 57(10):1392-1400. PubMed ID: 29775128
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin ototoxicity: the importance of baseline audiometry.
Nagy JL; Adelstein DJ; Newman CW; Rybicki LA; Rice TW; Lavertu P
Am J Clin Oncol; 1999 Jun; 22(3):305-8. PubMed ID: 10362343
[TBL] [Abstract][Full Text] [Related]
20. [Hearing loss caused by high dose carboplatin therapy].
Lautermann J; Adamczyk M; ten Cate WJ; Kloke O
Laryngorhinootologie; 1998 Feb; 77(2):82-4. PubMed ID: 9555700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
